#Japan #Tokyo #diabetes management #CGM System #Dexcom G7

Dexcom Japan Achieves Approval for Real-Time CGM System to Transform Diabetes Management

Dexcom Japan Introduces Groundbreaking Continuous Glucose Monitoring System

Dexcom Japan LLC, headquartered in Meguro, Tokyo, has achieved regulatory approval for its innovative real-time Continuous Glucose Monitoring (CGM) system known as the Dexcom G7 15Day CGM System. This advanced system is set to revolutionize the way diabetes is managed, providing significant improvements in patient care and convenience.

Key Features of the Dexcom G7 15Day CGM System

One of the standout features of the Dexcom G7 is its remarkable wearing period of 15 days. Traditional CGM systems typically require more frequent sensor replacements, which can be burdensome for patients. With the Dexcom G7, users only need to replace the sensors twice a month, allowing for continuous glucose monitoring without interruptions. This innovation supports uninterrupted data collection and helps in identifying glucose patterns effectively.

Furthermore, a reduction in the frequency of sensor changes is expected to significantly ease the burden on patients, enhancing overall convenience. The system employs a new algorithm that maintains high accuracy throughout the wearing period, which is crucial for effective blood glucose management. This, in turn, supports healthcare professionals in making informed treatment decisions, underscoring the system’s contribution to diabetes care.

Insights from Leadership

Motonori Asano, President of Dexcom Japan, highlighted the importance of this development:

“Diabetes is a lifelong condition that requires continuous treatment and self-management. By utilizing real-time CGM for blood glucose management, we aim to make numbers visible and help patients understand their fluctuations, facilitating behavior change. The approval of the Dexcom G7 15Day CGM System is a significant step in alleviating the burden related to treatment and management for our patients. We are committed to enhancing the quality of life for diabetes patients in Japan.”

Clinical Benefits and Accuracy

The features of the Dexcom G7 extend beyond just extended wear time. Clinical trials have confirmed the system's utility through randomized controlled studies. The high accuracy, ease of use, and reliability have been evaluated in clinical settings.

The system offers a Minimum Average Relative Difference (MARD) of 8.0%, with stable performance ranging from 7.3% to 8.9%. This consistency in accuracy reinforces the relevance of the data collected, thereby supporting clinical decision-making.

The Dexcom G7 15Day CGM System will be available to individuals aged 18 and older who are on insulin therapy under public health insurance in Japan.

The Importance of Continuous Monitoring

For individuals living with diabetes, understanding glucose fluctuations is critical in everyday health management. Continuous real-time CGM provides a visual representation of glucose trends, supporting effective blood sugar management strategies. By helping those with diabetes gain a better grasp of their health, the Dexcom G7 system is poised to enhance daily living.

With a mission to simplify blood sugar management for everyone, Dexcom aims to empower users through real-time data, paving the way for healthier lifestyles.

About Dexcom, Inc.

Founded in 1999, Dexcom is dedicated to providing innovative CGM technology worldwide to help people manage diabetes in real time. Headquartered in San Diego, California, the company has expanded its reach into Europe and Asia/Oceania, establishing itself as a technology leader in diabetes management. By operationalizing user feedback and collaborating with healthcare professionals, Dexcom continuously strives to simplify and improve diabetes care globally. For more information, visit Dexcom's website.